Behavioral Strategies to Lower Postprandial Glucose in Those with Type 2 Diabetes May Also Lower Risk of Coronary Heart Disease

Daniel J Cox, Kun Fang, Anthony L McCall, Mark R Conaway, Tom A Banton, Matthew A Moncrief, Anne M Diamond, Ann G Taylor, Daniel J Cox, Kun Fang, Anthony L McCall, Mark R Conaway, Tom A Banton, Matthew A Moncrief, Anne M Diamond, Ann G Taylor

Abstract

Introduction: Efforts to lower glycosylated hemoglobin (A1c) in patients with type 2 diabetes (T2D) are intended to reduce the risk of diabetic complications, but A1c is not the only factor contributing to this risk. Consequently, we re-analyzed published data from a broad-spectrum lifestyle intervention that lowered A1c to assess its effectiveness in lowering the overall risk of two complications of T2D, namely, coronary heart disease (CHD) and stroke.

Methods: Data from 37 adults who participated in a randomized clinical trial of a lifestyle intervention intended to reduce postprandial glucose (PPG) were re-analyzed for their pre- and post-treatment risk of CHD and stroke using the T2D-specific UK Prospective Diabetes Study (UKPDS) v2.0 risk algorithm.

Results: Compared to participants who received routine care, those using the lifestyle intervention had a significantly greater reduction in 10-year risk for CHD, but not for stroke.

Conclusion: These secondary analyses suggest that broad-spectrum lifestyle interventions that focus on lowering PPG may lower the risk of future CHD, which could guide future research.

Trial registration: ClinicalTrials.gov ID: NCT02432391.

Keywords: Behavioral medicine; Coronary disease; Postprandial hyperglycemia; Type 2 diabetes mellitus.

Figures

Fig. 1
Fig. 1
Mean predicted risk of coronary heart disease (CHD) and stroke for the Routine Care and Glycemic load, Exercise, and Monitoring blood glucose (GEM) study groups, pre- and post-treatment. Error bars depict standard errors of the means

References

    1. Taylor KS, Heneghan CJ, Farmer AJ. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care. 2013;36(8):2366–2371. doi: 10.2337/dc12-1513.
    1. Grundy S, Benjamin IJ, Burke GL. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–1146. doi: 10.1161/01.CIR.100.10.1134.
    1. Conway BN, May ME, Fischl A, Frisbee J, Han X, Blot WJ. Cause-specific mortality by race in low-income Black and White people with Type 2 Diabetes. Diabet Med. 2015;32:33–41. doi: 10.1111/dme.12563.
    1. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066–3072. doi: 10.1161/CIRCULATIONAHA.105.539528.
    1. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812–819. doi: 10.1016/j.amjmed.2006.02.031.
    1. Alberti KG, Eckel RH, Grundy SM. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640–1645. doi: 10.1161/CIRCULATIONAHA.109.192644.
    1. Look AHEAD Research Group Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–154. doi: 10.1056/NEJMoa1212914.
    1. Simonson DC, Halperin F, Foster K, Vernon A, Goldfine AB. Clinical and patient-centered outcomes in obese Type 2 Diabetes patients 3 years after randomization to Roux-en-Y gastric bypass surgery versus intensive lifestyle management: the SLIMM-T2D study. Diabetes Care. 2018;41(4):670–679. doi: 10.2337/dc17-0487.
    1. Cox DJ, Taylor AG, Singh H, et al. Glycemic load, exercise, and monitoring blood glucose (GEM): a paradigm shift in the treatment of type 2 diabetes mellitus. Diabetes Res Clin Pract; 2016;111(1):28–35.
    1. Cox DJ, Taylor AG, Moncrief M. Continuous glucose monitoring in the self-management of type 2 diabetes: a paradigm shift. Diabetes Care. 2016;39(5):e71–e73. doi: 10.2337/dc15-2836.
    1. Loprinzi PD, Addoh O. Predictive validity of the American College of Cardiology/American Heart Association pooled cohort equations in predicting all-cause and cardiovascular disease–specific mortality in a national prospective cohort study of adults in the United States. Mayo Clin Proc. 2016;91(6):763–769. doi: 10.1016/j.mayocp.2016.03.019.
    1. Adler AI. UKPDS—modelling of cardiovascular risk assessment and lifetime simulation of outcomes. Diabet Med. 2008;25:41–46. doi: 10.1111/j.1464-5491.2008.02498.x.
    1. Mannucci E, Monami M, Lamanna C, Adalsteinsson JE. Post-prandial glucose and diabetic complications: systematic review of observational studies. Acta Diabetol. 2012;49(4):307–314. doi: 10.1007/s00592-011-0355-0.
    1. Cavalot F, Petrelli A, Traversa M. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91(3):813–819. doi: 10.1210/jc.2005-1005.
    1. Aryangat AV, Gerich JE. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vascular Health Risk Manag. 2010;6:145.
    1. Hayes AJ, Leal J, Gray AM, et al. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56:1925–1933. doi: 10.1007/s00125-013-2940-y.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다